Evidence map›Paper›PMID 27549350›Full record

SynthesisCardiovascular diabetology2016

Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids.

Katherine E Beaney, Jackie A Cooper, Stela McLachlan, S Goya Wannamethee, Barbara J Jefferis, Peter Whincup, Yoav Ben-Shlomo, Jacqueline F Price, Meena Kumari, Andrew Wong and 10 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cardiovascular diabetology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 2 countries.

Katherine E BeaneyCentre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Science, University College London, University Street, London, UK.
Jackie A CooperCentre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Science, University College London, University Street, London, UK.
Stela McLachlanCentre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK.
S Goya WannametheeUCL Department of Primary Care & Population Health, UCL Institute of Epidemiology, University College London, London, UK.
Barbara J JefferisUCL Department of Primary Care & Population Health, UCL Institute of Epidemiology, University College London, London, UK.
Peter WhincupPopulation Health Research Institute, St George's University of London, Cranmer Terrace, London, UK.
Yoav Ben-ShlomoSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Jacqueline F PriceCentre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK.
Meena KumariInstitute for Social and Economic Research, University of Essex, Colchester, UK.
Andrew WongMRC Unit for Lifelong Health and Ageing, London, UK.
Ken OngMRC Unit for Lifelong Health and Ageing, London, UK.
Rebecca HardyMRC Unit for Lifelong Health and Ageing, London, UK.
Diana KuhMRC Unit for Lifelong Health and Ageing, London, UK.
Mika KivimakiDepartment of Epidemiology & Public Health, UCL Institute of Epidemiology & Health Care, University College London, London, UK.
Antti J KangasComputational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Pasi SoininenComputational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Mika Ala-KorpelaComputational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Fotios DrenosCentre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Science, University College London, University Street, London, UK. f.drenos@bristol.ac.uk.
Steve E HumphriesCentre for Cardiovascular Genetics, British Heart Foundation Laboratories, Institute of Cardiovascular Science, University College London, University Street, London, UK.
UCLEB consortium
British Heart Foundation · GBMRC Unit for Lifelong Health and Ageing · GBUniversity College London · GBUniversity of Eastern Finland · FIUniversity of Edinburgh · GBSt George's, University of London · GBUniversity of Bristol · GBUniversity of Essex · GBUniversity of Oulu · FI

Funding

Socio-economic status and heterogeneity in agingR01AG013196 · NIA · UNIVERSITY OF LONDON INST OF NEUROLOGY · PI MARMOT, MICHAEL G, SINGH-MANOUX, ARCHANA · 1996 to 2013
$3.5M
Socioeconomic gradient in CHD in early old ageR01HL036310 · NHLBI · UNIVERSITY OF LONDON · PI KIVIMAKI, MIKA J, MARMOT, MICHAEL G · 1986 to 2012
$3.1M
British Heart Foundation PG/09/024/26857British Heart Foundation RG/07/008/23674British Heart Foundation RG/08/013/25942British Heart Foundation RG/10/12/28456British Heart Foundation RG/13/16/30528Diabetes UK 10/0003985Medical Research Council G0500877Medical Research Council K013351Medical Research Council MC_UU_12013/5Medical Research Council MC_UU_12019/1Medical Research Council MR/K013351/1NHLBI NIH HHS R01 HL036310NIA NIH HHS R01 AG013196Wellcome Trust
6 · The paper itself

Abstract

aimsAn intergenic locus on chromosome 1 (lead SNP rs10911021) was previously associated with coronary heart disease (CHD) in type 2 diabetes (T2D). Using data from the UCLEB consortium we investigated the relationship between rs10911021 and CHD in T2D, whether rs10911021 was associated with levels of amino acids involved in the γ-glutamyl cycle or any conventional risk factors (CRFs) for CHD in the T2D participants.

methodsFour UCLEB studies (n = 6531) had rs10911021 imputation, CHD in T2D, CRF and metabolomics data determined using a nuclear magnetic resonance based platform.

resultsThe expected direction of effect between rs10911021 and CHD in T2D was observed (1377 no CHD/160 CHD; minor allele OR 0.80, 95 % CI 0.60-1.06) although this was not statistically significant (p = 0.13). No association between rs10911021 and CHD was seen in non-T2D participants (11218 no CHD/1274 CHD; minor allele OR 1.00 95 % CIs 0.92-1.10). In T2D participants, while no associations were observed between rs10911021 and the nine amino acids measured, rs10911021 was associated with HDL-cholesterol (p = 0.0005) but the minor "protective" allele was associated with lower levels (-0.034 mmol/l per allele). Focusing more closely on the HDL-cholesterol subclasses measured, we observed that rs10911021 was associated with six large HDL particle measures in T2D (all p < 0.001). No significant associations were seen in non-T2D subjects.

conclusionsOur findings are consistent with a true association between rs10911021 and CHD in T2D. The protective minor allele was associated with lower HDL-cholesterol and reductions in HDL particle traits. Our results indicate a complex relationship between rs10911021 and CHD in T2D.

Indexed as

Chromosomes, Human, Pair 1Polymorphism, Single NucleotideAgedAmino AcidsBiomarkersCholesterol, HDLCoronary DiseaseDiabetes Mellitus, Type 2DNA, IntergenicDown-RegulationFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHigh-Throughput Screening AssaysHumansAmino AcidsBiomarkersCholesterol, HDLDNA, IntergenicCoronary heart diseaseGenetic riskHDL-cholesterolMetabolomics

Identifiers

PMID27549350
PMCPMC4994200
OpenAlexW2508716146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.